The ColChinine Cardiovascular Outcomes Trial is usually put to effect in order to unravel the benefits of targeting inflammation after myocardial infarction. We are basically aimed to determine whether time-to-treatment is useful for ensuring that the best possible treatment is available to the people so that they do not have to lose their color, the patients were selected randomly assigned to receive the placebo within 30 days of starting the treatment. Therefore, at the end what matters is the fact that the maximum of the people is adapted to consume a quantity of 52 mg per day. These dosages play a vital role in curing the weaker parts of the body and saving the heart from all sorts of infection, which ultimately promises a great treatment to the same. The conclusion was the patients are able to benefit themselves from the study that has been conducted. The in-hospital injection of colchicine after MI plays a vital role in providing for the care.

REf art: